ADCETRIS 50 mg(Brentuximab Vedotin) is an antibody-drug conjugate (ADC) comprised of an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).
Manufacturer : Seattle Genetics
Strengths available : 50mg
Storage : store at temperature between 2°C - 8°C
FDA Approved : US FDA Approved
Date of Approval : August 19th, 2011
Dosage : For adults, the recommended dose of brentuximab vedotin (recombinant) is 1.8mg/kg of body weight administered as an intravenous infusion every 3 weeks. Dose can be reduced based on symptoms by patients.
Common side effects of Adcetris include fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, fever, rash or itching, stomach or abdominal pain, cough, vomiting, tired feeling, constipation, weight loss, swelling in your hands or feet, dry skin, hair loss, headache, dizziness, anxiety, muscle spasm, muscle or joint pain, night sweats, sleep problems (insomnia), low white blood cell count or low blood platelet count (neutropenia or thrombocytopenia), or tingling or numbness in the hands and feet.
Pack of 1 vial
Mehan Biosciences is a WHO GDSP approved & licensed Pharmaceutical stockist/wholesaler/distributor/exporter/importer of ADCETRIS Brentuximab Vedotin 50mg Inj based in India - To buy ADCETRIS Brentuximab Vedotin 50mg Inj or know its cost price contact us here.
We supply & sell ADCETRIS Brentuximab Vedotin 50mg Inj for Reference Listed Drugs, Government Tenders, Shortage Lists, Emergency Imports, Name Patient Drugs, Comparator Drug Studies, Un-licensed Importation, clinical trial samples & Bio-Similars.
At MBS, we acknowledge the critical role that reliable sourcing and timely delivery play in the healthcare industry. MBS is your trusted partner in pharmaceutical supply chain management.